WÅ‚adysÅ‚awa Anna Daniel

List of Publications by Year
in descending order

93 papers	2,183 citations	218381 26 h-index	276539 41 g-index
93 all docs	93 docs citations	93 times ranked	2386 citing authors

#	Article	IF	Citations
1	Cytochrome P450 2D (CYP2D) enzyme dysfunction associated with aging and serotonin deficiency in the brain and liver of female Dark Agouti rats. Neurochemistry International, 2022, 152, 105223.	1.9	8
2	The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. Biochemical Pharmacology, 2022, 199, 115006.	2.0	14
3	Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4. Pharmacological Reports, 2021, 73, 303-308.	1.5	6
4	The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms. Pharmaceuticals, 2021, 14, 629.	1.7	6
5	Treatment with dopamine Î²-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats. Pharmacological Reports, 2021, 73, 1694-1711.	1.5	3
6	The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms. International Journal of Molecular Sciences, 2021, 22, 8447.	1.8	4
7	The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 413-424.	1.5	13
8	Cytochrome P450 expression and regulation in the brain. Drug Metabolism Reviews, 2021, 53, 1-29.	1.5	49
9	The Selective NMDA Receptor GluN2B Subunit Antagonist CP-101,606 with Antidepressant Properties Modulates Cytochrome P450 Expression in the Liver. Pharmaceutics, 2021, 13, 1643.	2.0	3
10	Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects. Neurochemistry International, 2021, 151, 105209.	1.9	5
11	Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms. Cells, 2021, 10, 3472.	1.8	5
12	Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. Toxicology and Applied Pharmacology, 2020, 406, 115239.	1.3	8
13	The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat. Pharmacological Reports, 2020, 72, 1271-1287.	1.5	6
14	The effect of ageing and cerebral serotonin deficit on the activity of cytochrome P450 2D (CYP2D) in the brain and liver of male rats. Neurochemistry International, 2020, 141, 104884.	1.9	10
15	In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drugâ€“drug interactions. Pharmacological Reports, 2020, 72, 612-621.	1.5	26
16	The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions. Pharmacological Reports, 2020, 72, 1685-1694.	1.5	11
17	Stimulation of 5-HT2C serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver. Pharmacological Reports, 2019, 71, 1210-1212.	1.5	4
18	Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism. Scientific Reports, 2019, 9, 5262.	1.6	19

#	Article	IF	Citations
19	Serotonin Receptors of 5-HT₂ Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormoneâ€“Releasing Hormone/Growth Hormone Hormonal Pathway. Drug Metabolism and Disposition, 2019, 47, 80-85.	1.7	7
20	Activation of 5-HT1A Receptors in the Hypothalamic Paraventricular Nuclei Negatively Regulates Cytochrome P450 Expression and Activity in Rat Liver. Drug Metabolism and Disposition, 2018, 46, 786-793.	1.7	9
21	Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. European Journal of Medicinal Chemistry, 2018, 145, 790-804.	2.6	43
22	The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. Drug Metabolism Reviews, 2018, 50, 415-429.	1.5	35
23	The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. Biochemical Pharmacology, 2018, 156, 398-405.	2.0	19
24	The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression. Drug Metabolism and Disposition, 2017, 45, 1336-1344.	1.7	12
25	N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. ACS Medicinal Chemistry Letters, 2016, 7, 618-622.	1.3	42
26	The reverse role of the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei in the central serotonergic regulation of the liver cytochrome P450 isoform CYP2C11. Biochemical Pharmacology, 2016, 112, 82-89.	2.0	18
27	Desipramine administered chronically inhibits lipopolysaccharide-stimulated production of IL-1Î² in the brain and plasma of rats. Cytokine, 2016, 80, 26-34.	1.4	3
28	Melatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain. Drug Metabolism and Disposition, 2016, 44, 445-452.	1.7	24
29	Activation of brain serotonergic system by repeated intracerebral administration of 5-hydroxytryptophan (5-HTP) decreases the expression and activity of liver cytochrome P450. Biochemical Pharmacology, 2016, 99, 113-122.	2.0	18
30	Disruption of glucocorticoid receptors in the noradrenergic system leads to BDNF up-regulation and altered serotonergic transmission associated with a depressive-like phenotype in female GRDBHCre mice. Pharmacology Biochemistry and Behavior, 2015, 137, 69-77.	1.3	12
31	The role of the dorsal noradrenergic pathway of the brain (locus coeruleus) in the regulation of liver cytochrome P450 activity. European Journal of Pharmacology, 2015, 751, 34-41.	1.7	15
32	The cytochrome P450 2Dâ€mediated formation of serotonin from 5â€methoxytryptamine in the brain in vivo: a microdialysis study. Journal of Neurochemistry, 2015, 133, 83-92.	2.1	31
33	Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study. Pharmacological Reports, 2015, 67, 1178-1182.	1.5	8
34	Damage to the Brain Serotonergic System Increases the Expression of Liver Cytochrome P450. Drug Metabolism and Disposition, 2015, 43, 1345-1352.	1.7	21
35	The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: An in vitro study. Pharmacological Reports, 2014, 66, 1122-1126.	1.5	4
36	The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application. Biochemical Pharmacology, 2014, 90, 188-195.	2.0	17

#	Article	IF	Citations
37	Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacological Reports, 2013, 65, 1519-1528.	1.5	27
38	The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression. Biochemical Pharmacology, 2013, 86, 800-807.	2.0	21
39	Involvement of the paraventricular (PVN) and arcuate (ARC) nuclei of the hypothalamus in the central noradrenergic regulation of liver cytochrome P450. Biochemical Pharmacology, 2013, 86, 1614-1620.	2.0	27
40	Gender-dependent activity of CYP3A is indirectly modified by GR in the noradrenergic system. Pharmacological Reports, 2013, 65, 1431-1434.	1.5	3
41	Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver. Pharmacological Reports, 2013, 65, 1247-1255.	1.5	21
42	The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: An in vitro study. Pharmacological Research, 2013, 67, 53-59.	3.1	32
43	Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet. Pharmacological Research, 2012, 66, 292-299.	3.1	14
44	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacological Reports, 2012, 64, 1411-1418.	1.5	26
45	Autoinduction of the metabolism of phenothiazine neuroleptics in a primary culture of human hepatocytes. Pharmacological Reports, 2012, 64, 1578-1583.	1.5	3
46	Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver. Pharmacological Reports, 2011, 63, 1491-1499.	1.5	10
47	Cytochrome P450 is regulated by noradrenergic and serotonergic systems. Pharmacological Research, 2011, 64, 371-380.	3.1	28
48	Cytochrome P450 mediates dopamine formation in the brain in vivo. Journal of Neurochemistry, 2011, 118, 806-815.	2.1	70
49	The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. European Journal of Pharmacology, 2011, 651, 51-58.	1.7	24
50	Different Effects of Amitriptyline and Imipramine on the Pharmacokinetics and Metabolism of Perazine in Rats. Journal of Pharmacy and Pharmacology, 2010, 52, 1473-1481.	1.2	13
51	Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. Journal of Pharmacy and Pharmacology, 2010, 54, 1545-1552.	1.2	25
52	The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. Journal of Pharmacy and Pharmacology, 2010, 53, 449-461.	1.2	9
53	The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. European Journal of Pharmacology, 2010, 626, 171-178.	1.7	56
54	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liverâ€”A comparison with other phenothiazines. Biochemical Pharmacology, 2010, 80, 1252-1259.	2.0	58

#	Article	IF	Citations
55	Influence of antidepressant drugs on chlorpromazine metabolism in human liver -an in vitro study. Pharmacological Reports, 2010, 62, 1062-1069.	1.5	5
56	Effects of low doses of intracerebroventricular 6-OHDA on the levels of monoaminergic neurotransmitters in rat brain structures. Pharmacological Reports, 2010, 62, 1225-1230.	1.5	9
57	The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 631-645.	1.5	46
58	Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism â€“ an in vitro study. Pharmacological Reports, 2009, 61, 851-858.	1.5	17
59	Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacological Reports, 2009, 61, 1216-1220.	1.5	6
60	Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: The pathway and concentration dependence. Biochemical Pharmacology, 2008, 75, 1538-1549.	2.0	42
61	Regulation of liver cytochrome P450 by activation of brain dopaminergic system: Physiological and pharmacological implications. Biochemical Pharmacology, 2008, 76, 258-267.	2.0	49
62	The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: An in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochemical Pharmacology, 2008, 76, 543-551.	2.0	239
63	Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacological Reports, 2008, 60, 789-97.	1.5	77
64	Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacological Reports, 2008, 60, 957-65.	1.5	20
65	Identification of factors mediating the effect of the brain dopaminergic system on the expression of cytochrome P450 in the liver. Pharmacological Reports, 2008, 60, 966-71.	1.5	8
66	The Regulation of Liver Cytochrome P450 by the Brain Dopaminergic System. Current Drug Metabolism, 2007, 8, 631-638.	0.7	41
67	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacological Reports, 2007, 59, 296-305.	1.5	13
68	The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. Pharmacological Reports, 2007, 59, 606-12.	1.5	11
69	Caffeine metabolism during prolonged treatment of rats with antidepressant drugs. Pharmacological Reports, 2007, 59, 727-33.	1.5	5
70	The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. European Neuropsychopharmacology, 2006, 16, 178-186.	0.3	38
71	Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. European Neuropsychopharmacology, 2006, 16, 580-587.	0.3	34
72	Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1Î² levels in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 79-84.	1.4	8

#	Article	IF	Citations
73	CHARACTERIZATION OF HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF THE PIPERIDINE-TYPE PHENOTHIAZINE NEUROLEPTIC THIORIDAZINE. Drug Metabolism and Disposition, 2006, 34, 471-476.	1.7	58
74	Effect of mirtazapine on the CYP2D activity in the primary culture of rat hepatocytes. Pharmacological Reports, 2006, 58, 979-84.	1.5	2
75	The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 203-217.	1.5	34
76	Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivoâ€“possible involvement of different mechanisms. European Neuropsychopharmacology, 2005, 15, 103-110.	0.3	18
77	Effect of short- and long-term treatment with antidepressant drugs on the activity of rat CYP2A in the liver. Pharmacological Reports, 2005, 57, 774-81.	1.5	12
78	Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. Pharmacological Reports, 2005, 57, 867-71.	1.5	6
79	Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. Pharmacological Reports, 2005, 57, 872-7.	1.5	8
80	Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Research, 2004, 996, 168-179.	1.1	14
81	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. European Neuropsychopharmacology, 2004, 14, 199-208.	0.3	32
82	Effects of chronic treatment with classic and newer antidepressants and neuroleptics on the activity and level of CYP2D in the rat brain. Polish Journal of Pharmacology, 2004, 56, 857-62.	0.3	2
83	Contribution of human cytochrome P -450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. British Journal of Pharmacology, 2003, 138, 1465-1474.	2.7	49
84	Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 65-73.	2.5	81
85	Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study. Polish Journal of Pharmacology, 2003, 55, 1045-53.	0.3	8
86	Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes. Polish Journal of Pharmacology, 2003, 55, 1055-61.	0.3	6
87	The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. European Neuropsychopharmacology, 2002, 12, 371-377.	0.3	15
88	Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Polish Journal of Pharmacology, 2002, 54, 407-10.	0.3	6
89	Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. Polish Journal of Pharmacology, 2002, 54, 647-54.	0.3	15
90	Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. British Journal of Pharmacology, 2001, 134, 807-814.	2.7	49

#	Article	IF	Citations
91	Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. British Journal of Pharmacology, 2000, 131, 287-295.	2.7	36
92	The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. European Neuropsychopharmacology, 1999, 9, 337-344.	0.3	14
93	Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. European Neuropsychopharmacology, 1999, 9, 483-491.	0.3	45